FindTrial
Sign In

Tetrahydrobiopterin (BH4)

DRUG5 trials

Sponsors

The University of Texas Medical Branch, Galveston, Orphanetics Pharma Entwicklungs GmbH, Augusta University, VA Office of Research and Development

Conditions

Chronic Obstructive Pulmonary Disease (COPD)Heart Failure With Reduced Ejection FractionPhenylalanine Hydroxylase DeficienciesPhenylketonuriaPulmonary Disease, Chronic Obstructive

Early Phase 1

Exercise and NO in HFrEF
CompletedNCT03136029
VA Office of Research and DevelopmentHeart Failure With Reduced Ejection Fraction
Start: 2018-06-01End: 2025-07-31Updated: 2025-08-06

Phase 1

Response to Phenylketonuria to Tetrahydrobiopterin (BH4)
TerminatedNCT00244218
The University of Texas Medical Branch, GalvestonPhenylketonuria
Start: 2005-04-30End: 2015-01-31Updated: 2021-09-21

Phase 2

Long-Term Tetrahydrobiopterin Treatment in PKU Patients of 0-18 Years - Study on Phenylalanine Tolerance and Safety
TerminatedNCT00432822
Orphanetics Pharma Entwicklungs GmbHPhenylalanine Hydroxylase Deficiencies
Target: 50Updated: 2007-09-20
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
CompletedNCT02774226
Augusta UniversityChronic Obstructive Pulmonary Disease (COPD)
Start: 2015-09-30End: 2018-07-30Updated: 2021-02-23

Unknown Phase

Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01398943
Augusta UniversityPulmonary Disease, Chronic Obstructive
Start: 2010-09-30End: 2015-06-30Updated: 2017-12-11

Related Papers

Acute Tetrahydrobiopterin Improves Endothelial Function in Patients With COPD.
2018-04-2611 citations